### SECURITIES AND EXCHANGE COMMISSION

\ -	Washington, D.C. 20549
_	Form 8-K
	CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934	
August 7, 2003 (Date of earliest event reported)	

# BIOLASE TECHNOLOGY, INC.

Commission File Number 000-19627

(Exact Name of Registrant as Specified in Its Charter)

Delaware (State or Other Jurisdiction of Incorporation

000-19627 (Commission file 87-0442441 (I.R.S. Employer Identification No.)

or Organization)

number)

## Edgar Filing: BIOLASE TECHNOLOGY INC - Form 8-K

#### 981 Calle Amanecer

San Clemente, California 92673

(Address of Principal Executive Offices, Including Zip Code)

(949) 361-1200

(Registrant s Telephone Number, Including Area Code)

## Edgar Filing: BIOLASE TECHNOLOGY INC - Form 8-K

#### Item 7. Financial Statements and Exhibits.

- (c) Exhibits.
- 99.1 Press Release, dated August 7, 2003.

#### Item 12. Results of Operations and Financial Condition.

On August 7, 2003, BioLase Technology, Inc. issued a press release announcing that it and its independent accountants have decided to seek guidance from the Securities and Exchange Commission regarding the accounting affect of certain language in the BioLase s purchase order forms. A copy of the press release is attached herewith as Exhibit 99.1.

## Edgar Filing: BIOLASE TECHNOLOGY INC - Form 8-K

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: August 13, 2003 BIOLASE TECHNOLOGY, INC.,

(Registrant)

By: /s/ EDSON J. ROOD

Edson J. Rood

Vice President and

Chief Financial Officer

(Principal Financial and

Accounting Officer)